These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 35701011)

  • 1. Improved patient-reported outcomes in patients with psoriatic arthritis treated with risankizumab: analysis of the Phase 3 trial KEEPsAKE 2.
    Ostor AJK; Soliman AM; Papp KA; Padilla B; Wang Z; Eldred A; de Vlam K; Kivitz A
    RMD Open; 2022 Jun; 8(2):. PubMed ID: 35701011
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of risankizumab on achieving minimal clinically important differences in patient-reported outcomes in patients with psoriatic arthritis: results from KEEPsAKE 1 and 2.
    Kristensen LE; Soliman AM; Papp K; Barcomb L; Eldred A; Östör A
    J Eur Acad Dermatol Venereol; 2022 Nov; 36(11):2120-2129. PubMed ID: 35920763
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risankizumab improved health-related quality of life, fatigue, pain and work productivity in psoriatic arthritis: results of KEEPsAKE 1.
    Kristensen LE; Soliman AM; Papp K; White D; Barcomb L; Lu W; Eldred A; Behrens F
    Rheumatology (Oxford); 2023 Feb; 62(2):629-637. PubMed ID: 35801915
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tofacitinib or adalimumab versus placebo: patient-reported outcomes from OPAL Broaden-a phase III study of active psoriatic arthritis in patients with an inadequate response to conventional synthetic disease-modifying antirheumatic drugs.
    Strand V; de Vlam K; Covarrubias-Cobos JA; Mease PJ; Gladman DD; Graham D; Wang C; Cappelleri JC; Hendrikx T; Hsu MA
    RMD Open; 2019; 5(1):e000806. PubMed ID: 30713721
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patient-reported outcomes of upadacitinib versus abatacept in patients with rheumatoid arthritis and an inadequate response to biologic disease-modifying antirheumatic drugs: 12- and 24-week results of a phase 3 trial.
    Bergman M; Tundia N; Martin N; Suboticki JL; Patel J; Goldschmidt D; Song Y; Wright GC
    Arthritis Res Ther; 2022 Jun; 24(1):155. PubMed ID: 35751108
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 KEEPsAKE 2 trial.
    Östör A; Van den Bosch F; Papp K; Asnal C; Blanco R; Aelion J; Alperovich G; Lu W; Wang Z; Soliman AM; Eldred A; Barcomb L; Kivitz A
    Ann Rheum Dis; 2022 Mar; 81(3):351-358. PubMed ID: 34815219
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of tofacitinib on patient-reported outcomes in patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors in the phase III, randomised controlled trial: OPAL Beyond.
    Strand V; de Vlam K; Covarrubias-Cobos JA; Mease PJ; Gladman DD; Chen L; Kudlacz E; Wu J; Cappelleri JC; Hendrikx T; Hsu MA
    RMD Open; 2019; 5(1):e000808. PubMed ID: 30713722
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The impact of filgotinib on patient-reported outcomes and health-related quality of life for patients with active rheumatoid arthritis: a post hoc analysis of Phase 3 studies.
    Bingham CO; Walker D; Nash P; Lee SJ; Ye L; Hu H; Khalid JM; Combe B
    Arthritis Res Ther; 2022 Jan; 24(1):11. PubMed ID: 34980223
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improvement in Patient-Reported Outcomes in Patients with Psoriatic Arthritis Treated with Upadacitinib Versus Placebo or Adalimumab: Results from SELECT-PsA 1.
    Strand V; Mease PJ; Soriano ER; Kishimoto M; Salvarani C; Saffore CD; Zueger P; McDearmon-Blondell E; Kato K; Gladman DD
    Rheumatol Ther; 2021 Dec; 8(4):1789-1808. PubMed ID: 34636026
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bimekizumab provided rapid improvements in patient-reported symptoms and health-related quality of life in patients with active psoriatic arthritis: pooled 16-week results from two phase 3 studies.
    Husni ME; Mease PJ; Merola JF; Tillett W; Goldammer N; Ink B; Coarse J; Lambert J; Taieb V; Gladman DD
    RMD Open; 2024 Sep; 10(3):. PubMed ID: 39313302
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and Safety of Risankizumab for Active Psoriatic Arthritis: 100-Week Results from the KEEPsAKE 2 Randomized Clinical Trial.
    Östör A; Van den Bosch F; Papp K; Asnal C; Blanco R; Aelion J; Carter K; Stakias V; Lippe R; Drogaris L; Soliman AM; Chen MM; Padilla B; Kivitz A
    Rheumatol Ther; 2024 Jun; 11(3):633-648. PubMed ID: 38498139
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patient-reported outcomes from a phase 3 study of baricitinib versus placebo or adalimumab in rheumatoid arthritis: secondary analyses from the RA-BEAM study.
    Keystone EC; Taylor PC; Tanaka Y; Gaich C; DeLozier AM; Dudek A; Zamora JV; Cobos JAC; Rooney T; Bono S; Arora V; Linetzky B; Weinblatt ME
    Ann Rheum Dis; 2017 Nov; 76(11):1853-1861. PubMed ID: 28798049
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adalimumab improves joint-related and skin-related functional impairment in patients with psoriatic arthritis: patient-reported outcomes of the Adalimumab Effectiveness in Psoriatic Arthritis Trial.
    Gladman DD; Mease PJ; Cifaldi MA; Perdok RJ; Sasso E; Medich J
    Ann Rheum Dis; 2007 Feb; 66(2):163-8. PubMed ID: 17046964
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patient-reported outcomes from a randomized phase III trial of sarilumab monotherapy versus adalimumab monotherapy in patients with rheumatoid arthritis.
    Strand V; Gossec L; Proudfoot CWJ; Chen CI; Reaney M; Guillonneau S; Kimura T; van Adelsberg J; Lin Y; Mangan EK; van Hoogstraten H; Burmester GR
    Arthritis Res Ther; 2018 Jun; 20(1):129. PubMed ID: 29921318
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patient-Reported Outcomes in Psoriatic Arthritis Patients with an Inadequate Response to Biologic Disease-Modifying Antirheumatic Drugs: SELECT-PsA 2.
    Strand V; Van den Bosch F; Ranza R; Leung YY; Drescher E; Zueger P; Saffore CD; Lertratanakul A; Lippe R; Nash P
    Rheumatol Ther; 2021 Dec; 8(4):1827-1844. PubMed ID: 34661885
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of risankizumab for active psoriatic arthritis: 52-week results from the KEEPsAKE 2 study.
    Östör A; Van den Bosch F; Papp K; Asnal C; Blanco R; Aelion J; Lu W; Wang Z; Soliman AM; Eldred A; Padilla B; Kivitz A
    Rheumatology (Oxford); 2023 Jun; 62(6):2122-2129. PubMed ID: 36282537
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of intravenous golimumab on health-related quality of life and work productivity in patients with active psoriatic arthritis: results of the Phase 3 GO-VIBRANT trial.
    Ogdie A; Walsh JA; Chakravarty SD; Peterson S; Lo KH; Kim L; Li N; Hsia EC; Chan EKH; Kavanaugh A; Husni ME
    Clin Rheumatol; 2021 Sep; 40(9):3667-3677. PubMed ID: 33655380
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and Safety of Risankizumab for Active Psoriatic Arthritis: 100-Week Results from the Phase 3 KEEPsAKE 1 Randomized Clinical Trial.
    Kristensen LE; Keiserman M; Papp K; McCasland L; White D; Carter K; Lippe R; Photowala H; Drogaris L; Soliman AM; Chen M; Padilla B; Behrens F
    Rheumatol Ther; 2024 Jun; 11(3):617-632. PubMed ID: 38498141
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Associations between Patient Global Assessment scores and pain, physical function, and fatigue in rheumatoid arthritis: a post hoc analysis of data from phase 3 trials of tofacitinib.
    Strand V; Kaine J; Alten R; Wallenstein G; Diehl A; Shi H; Germino R; Murray CW
    Arthritis Res Ther; 2020 Oct; 22(1):243. PubMed ID: 33059710
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of tofacitinib on pain, fatigue, health-related quality of life and work productivity in patients with active ankylosing spondylitis: results from a phase III, randomised, double-blind, placebo-controlled trial.
    Navarro-Compán V; Wei JC; Van den Bosch F; Magrey M; Wang L; Fleishaker D; Cappelleri JC; Wang C; Wu J; Dina O; Fallon L; Strand V
    RMD Open; 2022 Jun; 8(2):. PubMed ID: 35654457
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.